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Abstract: Among all gynaecological neoplasms, ovarian cancer has the highest rate of disease-related
malnutrition, representing an important risk factor of postoperative mortality and morbidity. Hence,
the importance of finding effective nutritional interventions is crucial to improve ovarian cancer
patient’s well-being and survival. This systematic review of randomized controlled trials (RCTs)
aims at assessing the effects of nutritional interventions on clinical outcomes such as overall survival,
progression-free survival, length of hospital stay (LOS), complications following surgery and/or
chemotherapy in ovarian cancer patients. Three electronic bibliographic databases (MEDLINE,
Web of Science, and Cochrane Central Register of Controlled Trials) were used to conduct a systematic
literature search based on fixed inclusion and exclusion criteria, until December 2018. A total
of 14 studies were identified. Several early postoperative feeding interventions studies (n = 8)
were retrieved mainly demonstrating a reduction in LOS and an ameliorated intestinal recovery
after surgery. Moreover, innovative nutritional approaches such as chewing gum intervention
(n = 1), coffee consumption (n = 1), ketogenic diet intervention (n = 2) or fruit and vegetable juice
concentrate supplementation diet (n = 1) and short-term fasting (n = 1) have been shown as valid and
well-tolerated nutritional strategies improving clinical outcomes. However, despite an acceptable
number of prospective trials, there is still a lack of homogeneous and robust endpoints. In particular,
there is an urgent need of RCTs evaluating overall survival and progression-free survival during
ovarian oncology treatments. Further high-quality studies are warranted, especially prospective
studies and large RCTs, with more homogeneous types of intervention and clinical outcomes,
including a more specific sampling of ovarian cancer women, to identify appropriate and effective
nutritional strategies for this cancer, which is at high risk of malnutrition.
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1. Introduction
Ovarian cancer is one of the most common cancers worldwide with an estimated global incidence
in 2018 of 295,414 new cases [1]. Ovarian cancer has the highest mortality rate of all gynaecologic
cancers [2] with a poor five year survival rate. Older women are more likely to be initially diagnosed
with advanced disease, peaking in the seventh decade of life [3]. Due to the non-specific nature of
symptoms (dyspepsia, nausea, lack of appetite, fatigue, abdominal pain), patients may often be found
to have advanced disease with a wide intra-abdominal spread of neoplasms at the time of diagnosis.
One of the detrimental effects of the involvement of the intra-abdominal gastro-enteric apparatus is a
progressive reduction in caloric intake [4], contributing to the impairment of nutritional status and
body composition. As a consequence, women with this malignancy tend to have a higher incidence
of malnourishment at the time of diagnosis [5]. Since oncology treatments, such as surgery and
chemotherapy, produce additional adverse effects such as short bowel, diarrhoea, malabsorption and
fatigue [6], malnutrition in these cancer patients has a multifactorial origin and unfortunately is not
often recognized [7].
Among gynecologic malignancies, the prevalence of malnutrition is higher in ovarian cancer,
reaching 70% in some reports [4,8]. Many laboratory and clinical tools have been employed to identify
malnutrition in this setting, such as prealbumin or albumin [4,9,10], Nutritional Risk Score (NRS) [8],
Subjective Global Assessment (SGA) [11], and bioelectrical impedance analysis (BIA)-derived phase
angle [12]. These scores are able to predict longer hospital stays and impaired therapeutic outcomes in
malnourished patients [4,9–12].
All these findings underline the problem of malnutrition in ovarian cancer patients and highlight
the crucial need to propose adequate nutritional support in order to optimize their wellbeing and
maximize their ability to complete cancer treatments and consequently improve survival.
In recent years, a growing number of randomized clinical trials (RCTs) evaluated the effect of
nutritional support on clinical outcomes. This systematic review aims at examining the impact of
several types of nutrition interventions on clinical outcomes in ovarian cancer patients.
2. Materials and Methods
This systematic review was performed according to the Cochrane Handbook for systematic
reviews [13] and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [14].
2.1. Eligibility Criteria
2.1.1. Studies
Eligible study designs included RCTs including cross-over and parallel designs.
2.1.2. Participants
Eligible patients must (i) be at least 18 years old with any nutritional status (well-nourished,
malnourished, at risk of malnutrition) and (ii) have a histological diagnosis of epithelial ovarian cancer
having completed or not primary treatment (surgery, chemotherapy). Due to the limited number of
studies carried out on ovarian cancer patients only, we also considered studies on patients with ovarian
cancer and other gynecological cancers.
2.1.3. Interventions
Studies with nutritional interventions including nutrition assessment, nutrition counseling,
supplementary food or drink, fortified foods, oral nutrition supplements, enteral or parenteral feeds
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during chemotherapy or during the perioperative period were considered for inclusion in this review.
There were no restrictions on frequency, duration, and intensity of interventions. There was also no
limitation on intervention settings (e.g., hospital-based, home-based, individual/group counseling).
2.1.4. Outcomes
The outcomes of interest were overall survival, progression-free survival (PFS), length of hospital
stay (LOS), postoperative complications, anthropometry, and quality of life (QoL) measures, following
nutritional strategies.
2.2. Information Sources and Search Strategy
2.2.1. Electronic Searches
The search was carried out on 17 December 2018 using three electronic databases MEDLINE
(via PubMed), ISI Web of Science and Cochrane Central Register of Controlled Trials. The search
strategy was limited to English language articles and there were no restrictions on date of publication.
Databases were screened for search terms in titles and abstracts. The search string for each database is
described in Table 1.
Table 1. Full search strategies for three databases.
MEDLINE
Set Search Terms
1
diet*[TextWord] OR diet therapy[MeSHTerms] OR therapy nutrition[MeSHTerms] OR eat*[TextWord] OR food*[TextWord]
OR feed*[TextWord] OR meal*[TextWord] OR nutriment*[TextWord] or nutritional advice*[TextWord] OR nutritional
counseling*[TextWord] OR nutritional support*[TextWord] OR nutritional intervention*[TextWord]
2 ovar* [TextWord] OR ovary [MeSHTerms]
3 cancer*[TextWord] OR oncology[TextWord] OR tumour*[TextWord] OR tumor*[TextWord] OR malignan*[TextWord] ORcarcinoma[TextWord] OR neoplasm*[TextWord]
4 2 AND 3
5 1 AND 4
6 5 and Refined by: Publication Type: “Randomized Controlled Trial”
7 6 and Refined by: Subjects: “Humans”
WEB OF SCIENCE
Set Search Terms
1 Topic: (diet* OR eat* OR food* OR feed* OR meal* OR nutriment* or nutritional advice* OR nutritional therapy* ORnutritional support* OR nutritional intervention*)
2 Topic: (Ovarian OR Ovary)
3 Topic: (cancer* OR oncology OR tumour* OR tumor* OR malignan* OR carcinoma OR neoplasm*)
4 1 AND 2 AND 3
5
#4 AND Refined by: Topic: (randomised controlled trial* OR randomised controlled clinical trial* OR randomised controlled
study OR randomised controlled clinical study OR randomized controlled trial* OR randomized controlled clinical trial* OR
randomized controlled stud* OR randomized controlled clinical stud* OR randomised-controlled trial* OR
randomised-controlled clinical trial* OR randomised-controlled study OR randomised-controlled clinical study OR
randomized-controlled trial* OR randomized-controlled clinical trial* OR randomized-controlled stud* OR
randomized-controlled clinical stud*)
COCHRANE
Set Search Terms
1 Title Abstract Keyword: diet* OR eat* OR food* OR feed* OR meal* OR nutriment* or nutritional advice* OR nutritionaltherapy* OR nutritional support* OR nutritional intervention*
2 Title Abstract Keyword: ovarian OR ovary
3 Title Abstract Keyword: cancer* OR oncology OR tumour* OR tumor* OR malignan* OR carcinoma OR neoplasm*
4 1 AND 2 AND 3
Abbreviation: * star search algorithm.
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2.2.2. Hand Searches
Checking reference lists was used to supplement electronic searching. The reference lists of
retrieved articles were manually scrutinized to identify potentially relevant studies.
2.3. Study Selection
The study selection process was independently carried out by three reviewers (P.R; E.R; M.C). All
articles generated from the electronic search were imported into Mendeley© (Elsevier, Amsterdam, The
Netherlands), a reference management software, and duplicates were removed. Titles and abstracts
of all records were screened for eligibility based on inclusion criteria. All titles assessed as ineligible
were excluded. Differences in judgment during the selection process between the three reviewers were
settled by discussion and consensus.
2.4. Data Extraction
Information was collected using an Excel© (Microsoft Office, Redmond, WA, USA) spreadsheet
specifically developed for this study. Each full-text article was retrieved, and the articles deemed
ineligible were excluded and the reasoning reported. Differences in judgment between two reviewers
were settled by discussion and consensus.
2.5. Risk of Bias and Quality Assessment
The risk of bias instruments was used for randomized controlled trials and non randomized
comparative studies. Based on Cochrane’s guideline, risk of bias was independently assessed by at
least two reviewers, then the agreed assessment was further entered into the software Review Manager
5.3.5 (The Nordic Cochrane Centre, Copenhagen, Denmark).
The articles were assessed as high, low, or unclear risk using recommendations for judging the
risk of bias of the “Cochrane Handbook for Systematic Reviews of Interventions”. In total, there are
seven domains for quality assessment: (1) Random sequence generation; (2) Allocation concealment;
(3) Blinding of participants and personnel; (4) Blinding of outcome assessment; (5) Incomplete outcome
data; (6) Selective reporting; (7) Other bias (other source of bias could put the study at a high risk of
bias in certain circumstances, e.g., carry-over in cross-over trials, baseline imbalance). Each judgment
has three options: low risk, high risk, and unclear risk.
2.6. Data Synthesis
Because of the high heterogeneity of the studies’ measures and the types of nutritional intervention,
a systematic review was performed. Indeed, the measurement units, nutritional and control
interventions of each study were not comparable and consequently, meta-analysis was unfeasible.
The main results of the review were displayed on a summary of findings table. For each study, a
description of the population, type of intervention, outcomes measures and results were presented.
3. Results
3.1. Study Selection
The flow diagram in Figure 1 displays the results of the literature search and study selection process.
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diagram. 
Fourteen studies were identified for inclusion in the systematic review. Following the initial 
review of titles and abstracts and after hand searching, it was noted that the search strategy had not 
been sufficiently broad to identify all available studies in this area. Hand searching allowed the 
identification of fivesignificant studies.  
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Detailed study characteristics were retrieved in the Table 1.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009
flow diagram.
Fourteen studies were identified for inclusion in the systematic review. Following the initial
review of titles and str ts and after hand searching, it was noted t at the search strategy had
not been sufficiently broad to identify all v ilable studies in this area. Hand searching allowed the
identification of fivesignificant studies.
3.2. Study Characteristics
Detailed study characteristics e i the Table 2.
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Table 2. Characteristics of included studies.
Study ID Study Design Cancer Types with% Ovarian Cancer Sample Size
Time of
Intervention
Type of
Nutritional
Intervention
Comparison Outcomes Measures Results
Pearl et al. 1998
[15] RCT
Ovarian (32.3%),
cervical, uterine and
benign cancers
n = 195
Post-operation on
the first
postoperative day
EOF: Clear
liquid diet
TOF: Nothing by
mouth until bowel
sounds, the passage
of stool or flatus
• Incidence of vomiting
and nausea
• Intestinal function recovery
• LOS
• Postoperative complications
-No significant differences between the
two groups in:
• incidence of vomiting
• postoperative complications
-Significantly more patients in the EOF
group developed nausea (p = 0.006)
-Significantly reduction in the EOF
group of:
• time of development of bowel
sounds (p = 0.007)
• time to initiation of clear liquid
and regular diets (p < 0.001)
• LOS (p = 0.001)
Cutillo et al.
1999 [16]
RCT with
parallel arm
design
Ovarian (48.3%)
and other
gynecologic cancers
n = 122
Post-operation on
the first
postoperative day
EOF: Clear-fluid
diet, passing to
a semiliquid
fiberless diet
within the next
24 h
Nasogastric
decompression
followed by feeding
at the first passage
of flatus
• Incidence of nausea
and vomiting
• Intestinal function recovery:
time to first passage of flatus
and stool, time elapsed before
adequate tolerance of a
regular diet
• LOS
• Postoperative complications
-No significant differences between the
two groups in incidence of nausea and
vomiting.
-Significant reduction in the EOF
group of:
• time of resolution of
postoperative ileus(p < 0.01)
• time elapsed to a regular diet (p <
0.01)
• time of first passage of stool (p <
0.01)
• LOS (p < 0.05)
Pearl et al. 2002
[17] RCT
Ovarian (33%),
cervical, uterine and
benign cancers
n = 245
Post-operation on
the first
postoperative day
EOF: Regular
diet
EOF: Clear liquid
diet
• Incidence of nausea
and vomiting
• Abdominal distention,
passage of flatus
before discharge
• LOS
• Postoperative complications
-No significant differences between the
two groups in:
• incidence of nausea and vomiting
• abdominal distention
• time of first passage of flatus
before discharge
• LOS
• postoperative complications
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Table 2. Cont.
Study ID Study Design Cancer Types with% Ovarian Cancer Sample Size
Time of
Intervention
Type of
Nutritional
Intervention
Comparison Outcomes Measures Results
Feng et al. 2008
[18] RCT
Ovarian (18.3%)
and other
gynecologic cancers
n = 60
Post-operation on
the first 6
postoperative hours
Semiliquid diet
followed by
regular diet
Clear-liquid diet
tosemiliquid diet
toregular diet
• Incidence of nausea
and vomiting
• Time to development of
bowel sound and passage
of flatus
• Pre and post operative weight
• Urine acetone
• Fasting blood sugar
-Significant reduction (p < 0.05) in
clear feeds group of:
• incidence of nausea
• time of regular diet resumption
-No significant differences between the
two groups in:
• incidence of vomiting
• time to development of
bowel sound
• time of first passage of flatus
• pre and post operative weight
• urine acetone and fasting
blood sugar
Celik et al. 2009
[19]
RCT with
parallel arm
design
Ovarian (32%) and
other gynecologic
cancers
n = 50
Pre-operation on
the last 2
preoperative days
post-operation on
the first 7
postoperative days
IEN Standardenteralnutrition
• Nutritional measures
(albumin, prealbumin)
• LOS
• Postoperative complications
• Mortality rate.
-No significant differences between the
two groups in:
• nutritional measures
• mortality rate (p > 0.05)
-Significant reduction in patients
receiving IEN vs patients receiving
standard enteral nutrition in:
• LOS (p < 0.05)
• postoperative complications (p <
0.05) for wound infections
and dehiscence
Minig et al.
2009a [20] RCT
Ovarian cancer
(87.5%) n = 40
Post-operation
during the first 24
postoperative hours
EOF: Clear
liquid diet
TOF: Nothing by
mouth until the
resumption of
normal bowel
function
• LOS
• VAS score (abdominal pain)
• QoL (EORTC OV-28 and
EORTC C-30)
• EBL
• Incidence of nausea
and vomiting
• Postoperative complications
• Intestinal function recovery
• Analgesic and antiemetic
drugs requirements
-Significant reduction of LOS (p =
0.022) in EOF group vs TOF group.
-No significant differences between
both groups in:
• VAS score
• QoL
• EBL
• incidence of nausea and vomiting
• postoperative complications
• intestinal activity recovery
• analgesic and antiemetic
drugs needs
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Table 2. Cont.
Study ID Study Design Cancer Types with% Ovarian Cancer Sample Size
Time of
Intervention
Type of
Nutritional
Intervention
Comparison Outcomes Measures Results
Minig et al.
2009b [21] RCT
Ovarian (58%),
endometrial, cervix
and other cancers
n = 143
Post-operation
during the first 24
postoperative hours
EOF: Clear
liquid diet
TOF: Nothing by
mouth until the
resumption of
normal bowel
function
• LOS
• VAS score (Abdominal pain)
• QoL
• Incidence of nausea
and vomiting
• Postoperative complications
• Intestinal function recovery
• Analgesic and antiemetic
drugs requirements
-Significant reduction of LOS in the
EOF group (p = 0.006).
-Significant higher overall
postoperative (p = 0.003) and infective
complications (p = 0.017) in the TOF
group compared to the EOF group.
-Significant higher mean level of
postoperative satisfaction (p < 0.001) in
the EOF group.
-No differences between both groups
in:
• QoL
• incidence of nausea and vomiting
• abdominal pain
• analgesic and antiemetic
drugs requirements
Ertas et al. 2013
[22] RCT
Ovarian (36.9%),
endometrial and
cervix cancers
n = 149
Post-operation on
the first
postoperative
morning until the
first passage of
flatus
Chewing-gum 3
times/day Control
• Postoperative intestinal
function recovery
• LOS
-Significant reduction (p < 0.001) in
patients who chewed gum compared
to controls of:
• time to flatus and defecation
• time to bowel movement
• time to tolerate diet
• LOS
Baker et al. 2015
[23] RCT
Ovarian cancer
(100%) n = 109
Post-operationon
the first
postoperative day
Early enteral
feeding:
standard fiber
(20P:30F:50C)
125 kJ/kg body
weight.Until
adequate oral
intake could be
maintained:
65–75% of the
daily nutritional
requirements.
Standard oral diet
• QoL: FACT-G, FACT-O,
EQ5D index, Euroqol-VAS,
• ICU or HDU admission
• %Nausea/vomiting
• Blood transfusion %
• Nutritional status
(PG-SGA score)
• Pain score
• Weight
• Protein and energy intake
• LOS
-No significant differences between
both groups in:
• QoL
• LOS
• pain score
• Euroqol-VAS
• ICU or HDU admission
• % Nausea/vomiting
• blood transfusion %
• protein and energy intake
• weight
-Improvements of nutritional status
(PG-SGA score) in the early enteral
feeding patients vs. controls:
significant different (p < 0.05) at 7 days
postoperatively only
(intention-to-treat analysis).
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Table 2. Cont.
Study ID Study Design Cancer Types with% Ovarian Cancer Sample Size
Time of
Intervention
Type of
Nutritional
Intervention
Comparison Outcomes Measures Results
Güngördüket al.
2017 [24] RCT
Ovarian (39.5%),
endometrial,
cervical and
fallopian cancers
n = 114
Post-operationon
the first morning
after surgery
3 cups of
caffeinated
coffee daily (100
mL at 10:00 AM,
3:00 PM and /:00
PM)
Routine care
without coffee
consumption
• Intestinal activity recovery
(time to the first passage of
flatus after surgery, time to
first defecation, time to first
bowel movement, time to
toleration of a solid diet)
• LOS
-Significant reduction (p < 0.001) in
patients who consumed coffee
compared with controls in:
• time to flatus and defecation
• time to bowel movement
• time to tolerate diet.
-Reduction of LOS in patients who
consumed coffee compared to controls.
Bauersfeld et al.
2018 [25]
RCT with
cross-over
design
Ovarian (11.7%)
and breast cancers n = 34 During CT
Group ASTF* of
60 h (36 h before
to 24 h after CT)
during the first
three of
scheduled 6
CTsthenstandard
Mediterranean
diet during the
last three of
scheduled 6
CTs.
Group BStandard
Mediterranean diet
during the first
three of scheduled 6
CTsthenSTF* of 60 h
(36 h before to 24 h
after CT) during the
first three of
scheduled 6 CTs
• QoL: FACT-G
• Fatigue: FACIT-F
-In the group A, significant
improvements during fasted periods
compared to standard diet in:
• QoL
• fatigue
-In the group B, no significant
reduction during fasted period
compared to standard diet in
• QoL
• Fatigue
Cohen et al.
2018 [26] RCT
Ovarian (62.2%)
and endometrial
cancers
n = 45 During (n = 11) orpost-CT
KD diet (70:25:5
energy from fat,
protein, and
carbohydrate)
ACS diet: high fiber,
lower fat
• Body composition: android
fat mass, visceral fat,
lean mass
• Fasting serum insulin
-Significant reduction in the KD group
compared to the ACS group of:
• total and android fat mass (p <
0.05)
• percentage of change in visceral
fat (p < 0.05)
• fasting serum insulin (p < 0.01)
-No significant differences between
both groups in adjusted total lean
mass.
Cohen et al.
2018 [27]
RCT with
parallel arm
design
Ovarian (62.2%)
and endometrial
cancers
n = 45 During CT (n = 11)or post-CT
KD diet (70:25:5
energy from fat,
protein, and
carbohydrate)
ACS diet: moderate-
to
high-carbohydrate,
high fiber, low fat
• Mental function by Medical
Outcomes Study Short
Form-12 Health Survey
(SF-12
• Appetite (VAS)
• Food cravings by FCI
-No significant differences between
both groups in
• mental function
• hunger and appetite
-Less frequent food cravings in KD
group than ACS group at 12 weeks (p
< 0.05).
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Table 2. Cont.
Study ID Study Design Cancer Types with% Ovarian Cancer Sample Size
Time of
Intervention
Type of
Nutritional
Intervention
Comparison Outcomes Measures Results
Paxton et al.
2012 [28]
RCT with
parallel arm
design
Ovarian cancer
(100%) n = 52 Post-CT≥6 months LFHF group FVJC group
• Serum carotenoid and
tocopherol levels
• Dietary intake
• Weight
• QoL
-Significant improvements in both
groups (p < 0.01) in:
• serum carotenoid and
alpha-tocopherol levels
-Significant improvement in the LFHF
group (p < 0.05) in:
• dietary intake (fiber intake, daily
servings of juice fruits
and vegetables)
-No difference in both groups in:
• QoL
• Weight
Abbreviations: ACS, american cancer society; BMI, body mass index; C, carbohydrate; EBL, estimated blood loss; ECOG, eastern cooperative oncology group; EOF, early oral feeding;
EORTC, European Organization for the Research and Treatment of Cancer; F, fat; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FACT-G, Functional Assessment of
Cancer Therapy—General; FACT-O, Functional Assessment of Cancer Therapy—Ovarian; FCI, food craving inventory; FVJC, fruit and vegetable juice concentrates; HDU, high dependency
unit; ICU, intensive care unit; IEN, immunenhancing enteral nutrition; KD, ketogenic diet; LFHF, low fat high fibre; LOS, length of hospital stay; n, number; P, protein; PGA-SGA score,
Patient-Generated Subjective Global Assessment; Post-CT, post-chemotherapy treatment; QoL, quality of life; RCT, randomized controlled trial; STF, short-term fasting; TOF, traditional
oral feeding; CT, chemotherapy treatment; VAS, visual analogue scale. * Fasting period: unrestricted amounts of water, herbal tea, 2x100cl vegetable juice and small standardized quantities
of light vegetable broth with a maximum total daily energy intake of 350 kcal.
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3.3. Study Quality Assessment
The quality of the included studies was assessed in terms of risk of bias. The risk of bias across all
included studies is shown in Figure 2.
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None of the studies was assessed as fully low risk of bias. In seven studies, more than half of the
domains were assessed to be as low risk of bias [15–17,19,22,24,25].
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3.4. Summary of Findings
3.4.1. Effects of Nutritional Interventions on Overall Survival
Only one RCT evaluated the impact of a post-diagnosis nutritional intervention on overall survival
of patients with ovarian cancer. Celik et al. [19] compared immune-enhancing enteral nutrition (IEN)
with standard enteral feeding in oncologic gynecologic patients (32% of ovarian cancer patients) after
gynecologic oncologic surgery. This study demonstrated no significant differences in terms of mortality
rate (p > 0.05) between the two groups.
3.4.2. Effects of Nutritional Interventions on LOS
Nine RCTs evaluated the relationship between nutritional interventions and LOS of patients with
ovarian cancer.
Non-conventional postoperative feeding interventions were compared with postoperative
traditional oral diet in gynecological patients including ovarian cancer after oncologic
surgery [15–17,19–21,23]. In three RCTs [15,20,21], LOS of patients receiving early oral feeding (EOF)
was shorter than LOS of patients receiving traditional oral feeding (TOF). Indeed, in the first RCT
of Minig et al. [20], LOS was 6.9 ± 2.6 days in the EOF group versus (vs.) 9.1 ± 4.5 days in the TOF
group (p = 0.022). In the second study of Minig et al. [21], the reduction of LOS was confirmed with
4.7 ± 1.9 days in the EOF group vs 5.8 ± 2.3 days in the TOF group (p = 0.006). Finally, Pearl et al. [15]
demonstrated that LOS was significantly longer in the TOF group (4.6 ± 2.1 days in the EOF group vs.
5.8 ± 2.7 days in the TOF group; p = 0.001). Cutillo et al. [16] developed a RCT comparing, in ovarian
(48.3%) and other gynecologic cancer patients, early oral feeding (EOF) with nasogastric decompression
followed by feeding at the first passage of flatus, after major oncologic gynecologic surgery. Patients
receiving an EOF had a significantly shorter postoperative LOS than patients receiving a nasogastric
decompression followed by feeding at the first passage of flatus (median 5 days, range 3–18 vs. median
6 days, range 4–18; p < 0.05). However, the study of Baker et al. [23] did not find any significant
differences in LOS between ovarian cancer patients receiving postoperative early enteral feeding and
patients receiving a standard diet. Pearl et al. [17] showed a comparable LOS between gynecologic
cancer patients (including 33% of ovarian cancer patients) who received a regular diet on the first
postoperative day compared with patients who received a clear liquid diet as the first postoperative
meal. Finally, the use of immune-enhancing enteral nutrition (IEN) was compared with standard
enteral feeding in oncologic gynecologic patients (including 32% of ovarian cancer patients) after
abdominal surgery [19]. LOS was significantly shorter in IEN patients than standard enteral feeding
patients (4.1 ± 1.3 days vs. 7.8 ± 1.2 days; p < 0.05) [19].
Ertas et al. [22] evaluated an innovative postoperative gum-chewing intervention (30 min of
chewed gum, three times/day, from the first operative morning until the first passage of flatus) on
LOS of patients undergoing abdominal complete surgical staging for various gynecological cancers
including ovarian cancer. This study demonstrated that LOS was significantly reduced in patients that
chewed gum compared with controls (5.9 ± 1 vs. 7.0 ± 1.4 days; p < 0.001) [22]. Moreover, the impact of
coffee consumption was evaluated by Güngördük et al. [24]. This RCT showed that coffee consumption
during the early postoperative period after abdominal surgery reduces LOS (7.4 ± 2.9 days in the
control group vs. 6.1 ± 1.1 in the coffee group; p = 0.003).
3.4.3. Effects of Nutritional Interventions on Postoperative Clinical Outcomes
Nine studies evaluated the effect of nutritional interventions on postoperative functional activity
recovery of gynecologic cancer patients (including ovarian cancer) undergoing abdominal surgery
such as time to bowel motility (bowel sounds, flatus elimination, passage of stools), analgesic and
antiemetic requirements, time before solid diet tolerated, postoperative nausea and vomiting.
Patients who received the early clear liquid diet showed faster recovery of postoperative intestinal
function in terms of time to bowel sounds and time to flatus [15,20,21] compared to control group
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(clear liquid diet on the first postoperative day or nothing by mouth until the resumption of normal
bowel function). The time to development of bowel sounds (1.2 ± 0.5 days) and passage of flatus
(2.8 ± 1.4 days) were comparable between patients receiving a regular diet on the first postoperative
day and patients receiving a clear liquid diet as the first postoperative meal [17]. The incidence of
postoperative nausea in the early clear liquid diet feeding was nearly twice that of the traditional
feeding group (43.5% in the EOF group vs. 24.3% in the TOF group; p = 0.006) [15], whereas the
frequency of vomiting were comparable in both groups [15,21]. The incidence of nausea/ vomiting was
comparable between ovarian cancer patients who received a regular diet on the first postoperative day
and patients who received a clear liquid diet as the first postoperative meal [17]. In two RCTs [15,21],
the time to tolerance of solid diets was shorter in the early clear liquid diet group compared to the
traditional group. Additional requirements of analgesic and antiemetic drugs were similar between
the early clear liquid diet group and the traditional group [20,21]. The parallel design RCT of Cutillo et
al. [16] demonstrated that EOF reduced postoperative discomfort and allowed a more rapid recovery in
gynecologic patients (48.3% of ovarian cancer) [16]. Indeed, patients receiving an EOF were associated
with a significantly faster resolution of postoperative ileus (p < 0.01), a more rapid return to a regular
diet (3 days, range 2–14 vs. 5 days, range 2–8; p < 0.01) and an earlier first passage of stool (3 days,
range 1–10 vs. 4 days, range 1–8; p < 0.01) and flatus (2 days, range 1–4 vs. 3 days, range 1–6) than
patients receiving a nasogastric decompression. Nevertheless, rates of nausea and vomiting were
similar in both conditions. Moreover, Feng et al. [18] conducted a RCT comparing a semiliquid diet
with clear feeds, both started at 6 h in oncologic gynecologic patients (18.3% of ovarian cancer patients)
after major abdominal gynecological oncology surgery. There were significantly higher incidences of
nausea (17 patients vs. 7 patients; likelihood ratio χ2 = 6.944; p = 0.008) and a shorter time for regular
diet resumption in patients with semiliquid diet than in those with clear feeds (t = 4.112; p = 0.000) [18].
No significant differences were found in vomiting, in time to development of bowel sound and in
passage of flatus [18].
Other interventions such as gum-chewing [22] and coffee consumption [24] after surgery were
explored as adjuvant tools to improve bowel motility (first bowel movement, flatus, defecation time),
and the ability to tolerate food. Moreover, gum-chewing intervention significantly reduced analgesic
(relative risk RR = 7.8; 95% confidence interval CI: 1.0–61.5; p = 0.03) and antiemetic requirements (RR
= 4.8; 95% CI: 1.0–21.1; p = 0.03) compared to the control group.
3.4.4. Effects of Nutritional Interventions on Postoperative Complications
Regarding early postoperative feeding interventions, four RCTs assessed the impact of early
postoperative clear liquid diet feeding on the first postoperative day, compared to traditional oral
feeding. Two RCTs [15,20] observed a nonsignificant difference in the incidence of overall, infective
or intestinal complications between early clear diet group and traditional group. On the other hand,
Minig et al. performed another RCT [21] demonstrating significantly higher overall postoperative
complications in patients who received TOF than in patients receiving EOF (39% vs. 17% in the EOF
group; p= 0.003). Indeed, in this RCT, infective postoperative complications were significantly higher in
the TOF group (14% vs. 3%; p = 0.017) and the occurrence of postoperative ileus was higher in the TOF
than in the EOF branch, although this was not statistically significant (6% vs. 1%; p= 0.367). Additionally,
two patients in the TOF group required readmission (for fever syndrome and postoperative ileus)
vs. none in the EOF group [21]. Celik et al. [19] demonstrated that perioperative immunonutrition
decreased postoperative complications in patients undergoing surgery for gynecological malignancy
(including 32% of ovarian cancer patients) by increasing the immunologic response. Regarding the
influence of gum-chewing, the occurrence of mild ileus symptoms was higher in patients in the control
group compared to patients in the gum-chewing group (RR = 2.4; 95% CI: 1.2–4.5; p = 0.004) [22].
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3.4.5. Effects of Nutritional Interventions on Dietary Intake and Anthropometric Measures
Few studies evaluated the effect of different dietary prescriptions on patients’ dietary intake and
body weight or composition. Baker et al. reported no significant differences in protein and energy
intake and in weight increase between early postoperative enteral feeding group and traditional diet
group [23]. The parallel-arm RCT of Cohen et al. [26] compared the body composition of gynecologic
cancer patients (62.2% of ovarian cancer patients) assigned to the diet recommended by the American
Cancer Society (ACS) with the body composition of gynecologic cancer patients assigned to a ketogenic
diet (KD). This study demonstrated that the KD, compared with ACS diet, produced significantly
lower levels of adjusted total (35.3 kg compared with 38.0 kg; p < 0.05) and android (3.0 kg compared
with 3.3 kg; p < 0.05) fat mass. Paxton et al. found a significantly higher fiber intake (+5.2 g/day), daily
servings of juice (+0.9 servings/day) and vegetables (+1.3 servings/day) (all p < 0.05) in ovarian cancer
survivors consuming a low fat/high fiber (LFHF) diet compared with the arm consuming fruit and
vegetable juice concentrates (FVJC) diet [28]. However, no significant weight changes were appreciated
between the two groups [28].
3.4.6. Effects of Nutritional Interventions on QoL
The use of both an early postoperative enteral feeding [23], and an early postoperative resumption
of oral intake with a clear liquid diet [20,21] did not significantly improve patients’ well-being compared
to standard of care. Pain and QoL scores did not differ significantly between the groups [21]. The
impact of a 6 month dietary intervention (LFHF diet or FVJC diet) in ovarian cancer survivors was
studied by Paxton et al. [28]: in their study, no significant differences in Health-related QOL were
observed between LFHF group and FVJC group [28]. Cohen et al. [27] compared the impact of the diet
recommended by the ACS diet with a KD in patients with ovarian or endometrial cancer. Compared to
the ACS, the KD group improved perceived physical functional status as well as reduced cravings
for starchy food and fast food fats (p < 0.05 for both). These findings suggest that a KD is feasible for
ovarian cancer patients and may provide several benefits that improve QoL [27]. A recent cross over
pilot RCT [25] studied the effects of short-term fasting (STF)—36 h before and 24 h after chemotherapy
(60 h-fasting period) including a maximum total daily energy intake of 350 kcal on QoL and tolerance
to chemotherapy in patients with breast and ovarian cancer (11.7%). This study reported beneficial
effect of STF on QoL and fatigue during chemotherapy, in particular when STF was proposed in the
first half of chemotherapies cycles. Indeed, the chemotherapy-induced reduction of QoL was less
than the minimally important difference (MID; Functional Assessment of Cancer Therapy—General
(FACT-G) = 5) for STF, but greater than the MID for non-fasted periods.
4. Discussion
Disease-related malnutrition is well known to be an important risk factor of postoperative mortality
and morbidity in ovarian cancer patients [11,12]. As weight loss reduces the ability of patients to
be effectively treated with chemotherapy [29], the more oncologic patients are well-nourished by
receiving adequate nutritional support by clinicians, the better they are able to optimally withstand
cancer treatments.
This systematic review aimed at assessing whether nutritional interventions could improve
clinical outcomes, such as overall survival, PFS, LOS, clinical conditions and complications following
surgery, anthropometry and QoL measures in ovarian cancer patients during chemotherapy, or during
the perioperative period. Only RCTs were considered in order to conduct a meta-analysis and thus
obtain clear and valid conclusions, but all the reviewed RCTs were based on heterogeneous clinical
outcomes, used different nutritional interventions and control groups, thus resulting not suitable for
a meta-analysis.
The majority of RCTs reported improved clinical outcomes after nutritional
interventions [15,16,18–22,24,26–28]. Most of them found a reduction in LOS and ameliorated
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intestinal recovery after surgery [15,16,19,21,22,24]. In particular, patients receiving postoperative
early enteral feeding had significantly accelerated intestinal recovery following surgery [15,16,21].
Moreover, inexpensive nutritional strategies such as chewing gum use [22] and coffee consumption [24]
in the postoperative period have been shown as valid and well-tolerated tools to accelerate intestinal
recovery in gynecologic oncology patients, including ovarian cancer patients. Additionally, a parallel
trial [28] comparing a low-fat high-fiber diet (LFHF) to a fruit and vegetable juice concentrate (FVJC)
reported an improved energy intake in the LFHF group. Finally, up to now, only one trial [27]
demonstrated that KD did not negatively affect QoL (physical function, perceived energy), and that it
may decrease food cravings and induce selective fat mass loss without lean mass reduction in ovarian
or endometrial cancer patients.
The major strength of this review lies on the gathering of the latest researches on all the nutritional
strategies, including innovative nutritional interventions, in order to improve clinical outcomes
in ovarian cancer patients. Since the correlation between malnutrition, disease complications and
morbidity in oncology patients was demonstrated in different clinical settings [30–33], nutritional
and dietary management progressively have been under the spotlight in the field of gynecologic
malignancies in the last decade [8,11,34,35]. However, until now, the number of reviews on this
topic specifically addressing ovarian cancer remains very limited. Indeed, in recent years, only
one review [36] evaluated the impact of perioperative traditional early vs delayed oral fluids and
food, reporting a reduction of complications and LOS in ovarian cancer patients. The authors were
unable to identify any RCTs evaluating the use of nutrition supplementation or nutritional counselling
in women with ovarian cancer [36] and our review agrees with their conclusions. Indeed, due to
several limitations, we also cannot reach clear conclusions despite the rigorous methodology adopted.
Nevertheless, our review highlighted a few innovative nutritional approaches, such as high fibre
diet, fruit and vegetable juice concentrate supplementation [28], ketogenic diet intervention [27,28],
coffee [24] and chewing-gum [22] consumptions.
Furthermore, this review highlighted an intriguing crossover pilot study [25] which measured the
effect of STF during chemotherapy and reported improved tolerance to the treatment and QoL among
gynecologic patients (including 11.7% ovarian cancer patients). The scientific rationale of this study
relies on the results of in vitro and animal studies showing cancer cells sensitization to chemotherapy
after fasting for 48 h [37,38]. There is a growing interest on the effect of STF or fast-mimicking
diets (FMDs) during chemotherapy [39,40] and many clinical trials on this topic are ongoing [41–47].
However, these results should be taken with extreme caution [48]. Indeed, considering the lack of
strong clinical data (RCTs or prospective cohort studies with solid endpoints) on FMDs or STF, a
position paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial
Nutrition and Metabolism (SINPE) raised concerns particularly for malnourished patients [49]. Further
evidences are required to confirm the effects of STF and identify the right set of patients whom this
approach could be applied to and could really benefit from it [50].
Several limitations of the evidence shown in this systematic review require acknowledgment.
Firstly, only 2 out of 14 [23,28] included exclusively ovarian cancer patients. For this reason, RCTs
evaluating all gynecological cancer patients—including ovarian cancer—were also considered during
the data selection process. The majority of the reviewed RCTs used a mixed sample of gynecological
cancer patients and, in 8 out of 12 studies, less than 50% of the patients’ samples were ovarian
cancer [15–19,22,24,25]. Moreover, all these studies—in which ovarian cancer patients were categorised
as gynaecological cancer patients—did not report separate outcomes according to cancer type, making
it difficult to assess whether the results were consistent with ovarian cancer patients. Secondly, the
small sample sizes and the variations in cancer stage, treatment history, and concurrent chemotherapy
status of participants may also influence the results and represent a potential risk of bias. Thirdly, only
7 out of 14 RCTs performed a sample size calculation [16,20–22,24–26], making the validity of their
findings statistically reliable. Another limitation is the high risk of performance bias of all included
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studies. Indeed, it was not feasible to blind the participants due to the nutritional intervention received
and it may influence some nutritional intervention effect estimates.
5. Conclusions
Our systematic review highlighted the absence of data regarding the effect of nutritional
interventions on PFS during ovarian oncology treatments. Only one study [19] evaluated the effect
of immunonutrition on mortality rate. Regarding ovarian cancer, the importance to find nutritional
interventions in order to improve patient’s survival is even more crucial since the ovarian mortality
rate is one of the highest among malignancies [4,8].
Further high-quality studies, especially prospective studies and large RCTs, with more
homogeneity among types of intervention and clinical outcomes, including a large number of
ovarian cancer women, are required to propose new nutritional strategies and to investigate the effect
of such strategies as possible modifiers of relevant outcomes such as ovarian cancer survival and PFS.
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